Targeting Tau to Treat Clinical Features of Huntington's Disease

13Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by severe motor, cognitive and psychiatric impairments. While motor deficits often confirm diagnosis, cognitive dysfunctions usually manifest early in the disease process and are consistently ranked among the leading factors that impact the patients' quality of life. The genetic component of HD, a mutation in the huntingtin (HTT) gene, is traditionally presented as the main contributor to disease pathology. However, accumulating evidence suggests the implication of the microtubule-associated tau protein to the pathogenesis and therefore, proposes an alternative conceptual framework where tau and mutant huntingtin (mHTT) act conjointly to drive neurodegeneration and cognitive dysfunction. This perspective on disease etiology offers new avenues to design therapeutic interventions and could leverage decades of research on Alzheimer's disease (AD) and other tauopathies to rapidly advance drug discovery. In this mini review, we examine the breadth of tau-targeting treatments currently tested in the preclinical and clinical settings for AD and other tauopathies, and discuss the potential application of these strategies to HD.

Cite

CITATION STYLE

APA

Masnata, M., Salem, S., de Rus Jacquet, A., Anwer, M., & Cicchetti, F. (2020, November 19). Targeting Tau to Treat Clinical Features of Huntington’s Disease. Frontiers in Neurology. Frontiers Media S.A. https://doi.org/10.3389/fneur.2020.580732

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free